Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2005
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune diseaseKatharine A Whartenby, Peter A Calabresi, Erin McCadden, et al.
Blood|March 31, 2005
Internal tandem duplications of the FLT3 gene are present in leukemia stem cellsMark Levis, Kathleen M Murphy, Rosalyn Pham, et al.
Oncotarget|September 26, 2018
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3Kozo Nagai, Lihong Hou, Li Li, et al.
Blood Advances|April 29, 2021
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysisDavid J Young, Bao Nguyen, Ruiqi Zhu, et al.
Blood|April 19, 2007
The incidence and clinical significance of nucleophosmin mutations in childhood AMLPatrick Brown, Emily McIntyre, Rachel Rau, et al.
Blood|January 17, 2004
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemiaB Douglas Smith, Mark Levis, Miloslav Beran, et al.
Blood|February 11, 2012
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse modelSarah Greenblatt, Li Li, Christopher Slape, et al.
Experimental and Molecular Pathology|June 23, 2010
FLT-3 expression and function on microglia in multiple sclerosisCynthia A DeBoy, Horea Rus, Cosmin Tegla, et al.
Oncotarget|November 20, 2018
Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in miceColleen E Annesley, Cara Rabik, Amy S Duffield, et al.
Molecular Oncology|October 12, 2024
Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemiaTessa S Seale, Li Li, J Kyle Bruner, et al.
Pageof 9